We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Oscar Health Skyrockets 109% YTD: Time to Bet on the Stock Now?
Read MoreHide Full Article
Key Takeaways
Oscar Health shares have surged 109% YTD, outperforming its industry, sector and S&P 500 composite.
Membership rose 46% to 2.96 million, while second-quarter revenues jumped 70% to $4.88 billion.
OSCR plans more than 150 new metro areas by 2027 and targets a 20% revenue CAGR and 5% operating margin.
Shares of Oscar Health (OSCR - Free Report) have gained 108.5% year to date, outperforming the industry, its sector, as well as the Zacks S&P 500 composite in the same time frame. OSCR shares are trading at a discount to their 52-week high.
The surge likely reflects a major profitability turnaround at Oscar Health. Strong ACA membership growth, higher revenue, improved medical-loss ratios, and better cost management significantly boosted earnings. Management’s substantial increase in 2026 profit guidance further strengthened investor confidence, leading to a major rerating of the stock.
Oscar is a leading healthcare technology company built around a full-stack technology platform. It is well-positioned for sustained growth as it strengthens its presence in the expanding U.S. individual health insurance market.
OSCR vs Industry, Sector, S&P 500 YTD
Image Source: Zacks Investment Research
Oscar’s peer, Molina Healthcare (MOH - Free Report) , a government-focused managed-care insurer with Marketplace and Medicaid exposure, has gained 51.1% year to date, while another peer, Centene (CNC - Free Report) , a major managed-care insurer with substantial ACA Marketplace exposure, has gained 68.5% in the same time frame.
OSCR Shares Are Expensive
The stock is overvalued compared with its industry. It is currently trading at a price-to-book multiple of 4.5, higher than the industry average of 2.67 and the median of 2.64 over five years. It has a Value Score of B.
Image Source: Zacks Investment Research
OSCR is expensive compared to Molina Healthcare and Centene.
The Case for OSCR Stock
Structural shifts in employment—including the rise of gig work, part-time jobs, self-employment and early retirement—are increasing demand for portable health insurance outside traditional employer-sponsored plans. Oscar Health is well-positioned to capitalize on this trend through its differentiated technology platform, which integrates plan design, member engagement, care navigation, claims processing and provider management. Its Individual Coverage Health Reimbursement Arrangements, Lucie Health marketplace and Trove Group also create growth opportunities beyond the core insurance business.
Strong membership growth reflects rising acceptance of Oscar’s offerings. Membership reached 2.96 million as of June 30, 2026, up 46% year over year. Second-quarter revenues jumped 70% to $4.88 billion, supported by membership gains and premium-rate increases. Oscar expects 2026 revenues of $18.7-$19.0 billion, demonstrating its growing scale in the individual insurance market.
The company plans to enter more than 150 additional metropolitan statistical areas by 2027. Disciplined pricing, consumer-focused products and a scalable technology platform should support continued expansion in the Affordable Care Act marketplace. Oscar’s strategy also aligns with major healthcare trends, including rising costs, consumerization, digitization and greater personalization. Its early focus on these areas could provide a sustainable competitive advantage as the healthcare system evolves.
Management targets a 20% revenue CAGR through 2027 and a 5% operating margin next year. Technology and AI initiatives, fixed-cost leverage and lower risk-adjustment expenses as a percentage of premiums are already helping improve the expense ratio.
Oscar’s financial position has also strengthened. As of June 30, 2026, it held approximately $4.08 billion in cash and cash equivalents and $6.08 billion in investments, compared with long-term debt of roughly $432 million. This liquidity provides ample flexibility to meet regulatory capital requirements, fund technology investments and support continued membership growth.
Optimistic Analyst Sentiment
The Zacks Consensus Estimate for 2026 and 2027 revenues indicates a 60.8% and 9.6% year-over-year increase, respectively. The same for 2026 and 2027 earnings implies a 191.2% and 15.8% year-over-year increase, respectively.
The expected earnings growth rate is pegged at 31.5%, better than the industry average of 12.8%. The company has a Growth Score of A.
The consensus estimate for 2026 and 2027 earnings has moved 144.4% and 31.6% north, respectively, in the past 30 days.
Image Source: Zacks Investment Research
The consensus estimates for 2026 and 2027 earnings of Molina Healthcare, as well as Centene, witnessed upward movement in the past 30 days.
How to Play OSCR Shares
Oscar’s expanding membership, improving cost structure, scalable technology platform, consistent underwriting discipline and solid balance sheet will help it convert its strong results into durable earnings. Its VGM Score of A instills confidence.
View the Zacks #1 Rank List
Image: Bigstock
Oscar Health Skyrockets 109% YTD: Time to Bet on the Stock Now?
Key Takeaways
Shares of Oscar Health (OSCR - Free Report) have gained 108.5% year to date, outperforming the industry, its sector, as well as the Zacks S&P 500 composite in the same time frame. OSCR shares are trading at a discount to their 52-week high.
The surge likely reflects a major profitability turnaround at Oscar Health. Strong ACA membership growth, higher revenue, improved medical-loss ratios, and better cost management significantly boosted earnings. Management’s substantial increase in 2026 profit guidance further strengthened investor confidence, leading to a major rerating of the stock.
Oscar is a leading healthcare technology company built around a full-stack technology platform. It is well-positioned for sustained growth as it strengthens its presence in the expanding U.S. individual health insurance market.
OSCR vs Industry, Sector, S&P 500 YTD
Image Source: Zacks Investment Research
Oscar’s peer, Molina Healthcare (MOH - Free Report) , a government-focused managed-care insurer with Marketplace and Medicaid exposure, has gained 51.1% year to date, while another peer, Centene (CNC - Free Report) , a major managed-care insurer with substantial ACA Marketplace exposure, has gained 68.5% in the same time frame.
OSCR Shares Are Expensive
The stock is overvalued compared with its industry. It is currently trading at a price-to-book multiple of 4.5, higher than the industry average of 2.67 and the median of 2.64 over five years. It has a Value Score of B.
Image Source: Zacks Investment Research
OSCR is expensive compared to Molina Healthcare and Centene.
The Case for OSCR Stock
Structural shifts in employment—including the rise of gig work, part-time jobs, self-employment and early retirement—are increasing demand for portable health insurance outside traditional employer-sponsored plans. Oscar Health is well-positioned to capitalize on this trend through its differentiated technology platform, which integrates plan design, member engagement, care navigation, claims processing and provider management. Its Individual Coverage Health Reimbursement Arrangements, Lucie Health marketplace and Trove Group also create growth opportunities beyond the core insurance business.
Strong membership growth reflects rising acceptance of Oscar’s offerings. Membership reached 2.96 million as of June 30, 2026, up 46% year over year. Second-quarter revenues jumped 70% to $4.88 billion, supported by membership gains and premium-rate increases. Oscar expects 2026 revenues of $18.7-$19.0 billion, demonstrating its growing scale in the individual insurance market.
The company plans to enter more than 150 additional metropolitan statistical areas by 2027. Disciplined pricing, consumer-focused products and a scalable technology platform should support continued expansion in the Affordable Care Act marketplace. Oscar’s strategy also aligns with major healthcare trends, including rising costs, consumerization, digitization and greater personalization. Its early focus on these areas could provide a sustainable competitive advantage as the healthcare system evolves.
Management targets a 20% revenue CAGR through 2027 and a 5% operating margin next year. Technology and AI initiatives, fixed-cost leverage and lower risk-adjustment expenses as a percentage of premiums are already helping improve the expense ratio.
Oscar’s financial position has also strengthened. As of June 30, 2026, it held approximately $4.08 billion in cash and cash equivalents and $6.08 billion in investments, compared with long-term debt of roughly $432 million. This liquidity provides ample flexibility to meet regulatory capital requirements, fund technology investments and support continued membership growth.
Optimistic Analyst Sentiment
The Zacks Consensus Estimate for 2026 and 2027 revenues indicates a 60.8% and 9.6% year-over-year increase, respectively. The same for 2026 and 2027 earnings implies a 191.2% and 15.8% year-over-year increase, respectively.
The expected earnings growth rate is pegged at 31.5%, better than the industry average of 12.8%. The company has a Growth Score of A.
The consensus estimate for 2026 and 2027 earnings has moved 144.4% and 31.6% north, respectively, in the past 30 days.
Image Source: Zacks Investment Research
The consensus estimates for 2026 and 2027 earnings of Molina Healthcare, as well as Centene, witnessed upward movement in the past 30 days.
How to Play OSCR Shares
Oscar’s expanding membership, improving cost structure, scalable technology platform, consistent underwriting discipline and solid balance sheet will help it convert its strong results into durable earnings. Its VGM Score of A instills confidence.
Optimistic analyst sentiment, price appreciation and discounted valuation make this Zacks Rank #2 (Buy) stock a strong contender for addition to one’s portfolio. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.